Delighted to announce our participation in the Progress study – Oxford Nanopore Technologies

Emmanuella-Faith Amoako, Paediatric Haematologist Oncologist, Director of Clinical Affairs Yemaachi Biotech, shared a post on Linkedin by Oxford Nanopore Technologies, adding:

“This couldn’t have come at a better time!!! September is childhood cancer awareness month and it is exciting to showcase the interesting work we are doing in Ghana! For Africa in Africa! This brings me so much joy. There is hope for a cure for the African child. In keeping with World Health Organization’s GICC, we hope to bring cure rates to 60% globally.”

Quoting Oxford Nanopore Technologies’s post:

”We are delighted to announce our participation in the Progress study, with Yemaachi Biotech, which aims to address the pressing issue of childhood cancer in Africa, with a view to setting a new standard for future diagnosis and treatment in resource-limited settings.

The Progress study aims to pilot the use of nanopore sequencing for minimal residual disease (MRD) detection in paediatric acute lymphoblastic leukaemia (ALL) in Ghana.

The study may show how Oxford Nanopore’s platform, capable of accurately detecting clinically actionable genetic variants, is crucial for effective risk stratification and potential treatment changes.

Approaches developed by the Ryan lab at Newcastle University will be utilised, marking an exciting leap-frog opportunity, as this is not yet standard of care in the US or Europe.”

Find out more.
Source: Emmanuella-Faith Amoako/Linkedin and Oxford Nanopore Technologies/Linkedin